A new US biotech start-up, Kinaset Therapeutics, founded to develop new therapies for asthma, will have as its lead compound a novel pan-JAK inhibitor, KN-002, which is licensed from the UK inhalation specialist company Vectura Group plc and is expected to enter clinical studies in the first half of 2021.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?